16.85
+0.37(+2.25%)
Currency In USD
| Previous Close | 16.48 |
| Open | 16.48 |
| Day High | 16.89 |
| Day Low | 16.05 |
| 52-Week High | 50.4 |
| 52-Week Low | 15.36 |
| Volume | 420,161 |
| Average Volume | 1.21M |
| Market Cap | 470.3M |
| PE | -8.18 |
| EPS | -2.06 |
| Moving Average 50 Days | 24.49 |
| Moving Average 200 Days | 30.74 |
| Change | 0.37 |
If you invested $1000 in LENZ Therapeutics, Inc. (LENZ) since IPO date, it would be worth $1,040.12 as of January 07, 2026 at a share price of $16.85. Whereas If you bought $1000 worth of LENZ Therapeutics, Inc. (LENZ) shares 1 year ago, it would be worth $619.94 as of January 07, 2026 at a share price of $16.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East
GlobeNewswire Inc.
Jan 05, 2026 1:00 PM GMT
Exclusive distribution agreement includes revenue sharing in addition to upfront and milestone payments to LENZSAN DIEGO and DUBAI, United Arab Emirates, Jan. 05, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lunatus Marketing
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
GlobeNewswire Inc.
Dec 01, 2025 1:30 PM GMT
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZSAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co.
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
GlobeNewswire Inc.
Oct 29, 2025 12:00 PM GMT
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-ap